Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function

Aymone Gurtner1, Giuseppe Starace, Giuseppe Norelli

  • 1Molecular Oncogenesis Laboratory, Department of Experimental Oncology, Regina Elena Cancer Institute, Via delle Messi D'Oro 156, 00158 Rome, Italy.

Insights

Gain-of-function p53 mutants regulate MAP2K3 expression, promoting cancer cell proliferation and survival. Targeting MAP2K3 offers a novel strategy against mutant p53-driven cancers.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Signal Transduction

Background:

  • Mitogen-activated protein kinase kinase 3 (MAP2K3) is implicated in cancer invasion and progression.
  • Gain-of-function (GOF) p53 mutants are frequently observed in human cancers and contribute to tumor development.
  • Understanding the regulatory mechanisms of MAP2K3 in cancer is crucial for therapeutic development.

Purpose of the Study:

  • To investigate MAP2K3 as a transcriptional target of endogenous GOF p53 mutants.
  • To elucidate the molecular mechanisms by which GOF p53 mutants regulate MAP2K3.
  • To determine the functional role of MAP2K3 in cancer cell proliferation and survival under GOF p53 conditions.

Main Methods:

  • Identification of MAP2K3 as a transcriptional target using p53 mutant expression models.
  • Analysis of MAP2K3 mRNA and protein levels.
  • Chromatin immunoprecipitation assays to assess p53 binding to the MAP2K3 promoter.
  • Reporter assays to evaluate promoter activity.
  • Knockdown and ectopic expression studies of MAP2K3 in human tumor cells.

Main Results:

  • Endogenous GOF p53 mutants (R273H, R175H, R280K) directly activate the MAP2K3 promoter.
  • MAP2K3 expression is modulated at both mRNA and protein levels by these p53 mutants.
  • Transcriptional cofactors NF-Y and NF-kappaB are involved in p53-mediated MAP2K3 regulation.
  • MAP2K3 knockdown inhibits proliferation and survival of human tumor cells.
  • Ectopic MAP2K3 expression rescues the proliferative defect caused by mutant p53 knockdown.

Conclusions:

  • MAP2K3 is a novel transcriptional target of GOF p53 mutants.
  • Mutant p53 promotes cancer cell proliferation and survival through the upregulation of MAP2K3.
  • MAP2K3 represents a potential therapeutic target for cancers harboring GOF p53 mutations.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...